A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy.
暂无分享,去创建一个
Jing-Wen Ma | Zhi-Hua Huang | Yong-Xiang Chen | Yan‐Mei Li | Lei Shi | Yan-Mei Li | Yu-Fen Zhao | Hui Cai | Zhan-Yi Sun | Yu-Fen Zhao | Yong-Xiang Chen | Lei Shi | H. Cai | Zhi-Hua Huang | Z. Sun | Jing-wen Ma | Zhan-yi Sun | Zhan-yi Sun | Zhan-yi Sun
[1] C. Snapper,et al. T cell-independent antigens type 2. , 1995, Annual review of immunology.
[2] Jangwook P. Jung,et al. Co-assembling peptides as defined matrices for endothelial cells. , 2009, Biomaterials.
[3] J. Unkeless,et al. The presence of two Fc receptors on mouse macrophages: evidence from a variant cell line and differential trypsin sensitivity , 1977, The Journal of experimental medicine.
[4] G. Boons,et al. The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. , 2004, Chemistry.
[5] Zhongwu Guo,et al. Recent development in carbohydrate-based cancer vaccines. , 2009, Current opinion in chemical biology.
[6] Thomas C. Mitchell,et al. The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4 , 2007, Science.
[7] H. Kunz,et al. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and bovine serum albumin. , 2005, Angewandte Chemie.
[8] W. Paul,et al. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. , 1987, Science.
[9] Yan‐Mei Li,et al. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry. , 2011, Chemistry.
[10] H. Kunz,et al. Synthetic glycopeptides from the mucin family as potential tools in cancer immunotherapy. , 2006, Current cancer drug targets.
[11] M. Neuberger,et al. Activation of mouse complement by monoclonal mouse antibodies , 1981, European journal of immunology.
[12] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[13] S. Akira,et al. Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.
[14] E. Schmitt,et al. Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2. , 2010, Angewandte Chemie.
[15] M. Wolfert,et al. Robust immune responses elicited by a fully synthetic three-component vaccine. , 2007, Nature chemical biology.
[16] Jangwook P. Jung,et al. A self-assembling peptide acting as an immune adjuvant , 2009, Proceedings of the National Academy of Sciences.
[17] Peng Zou,et al. Synthesis of Tn/T Antigen MUC1 Glycopeptide BSA Conjugates and Their Evaluation as Vaccines , 2011 .
[18] Zhongwu Guo,et al. Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse. , 2012, ACS chemical biology.
[19] Ravibhushan Singh,et al. MUC1: A target molecule for cancer therapy , 2007, Cancer biology & therapy.
[20] E. Schmitt,et al. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response. , 2005, Angewandte Chemie.
[21] M. Skwarczynski,et al. Peptide-based subunit nanovaccines. , 2011, Current drug delivery.
[22] Yan‐Mei Li,et al. Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response. , 2012, Angewandte Chemie.
[23] Qian Wan,et al. From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine. , 2009, Journal of the American Chemical Society.
[24] Brendan L Wilkinson,et al. Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. , 2011, Angewandte Chemie.
[25] John A. Robinson,et al. Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system. , 2007, Angewandte Chemie.
[26] Shizuo Akira,et al. Toll-like receptor signalling , 2004, Nature Reviews Immunology.
[27] E. Schmitt,et al. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response. , 2008, Angewandte Chemie.
[28] D. Scheinberg,et al. Toward a Prostate Specific Antigen-Based Prostate Cancer Diagnostic Assay: Preparation of Keyhole Limpet Hemocyanin -Conjugated Normal and Transformed Prostate Specific Antigen Fragments , 2008, Journal of the American Chemical Society.